Scientists have used newly developed nanotechnology chips (multidimensional and multiplexed immune monitoring assays) to successfully monitor T cells genetically engineered to attack melanoma. They have discovered that the T cells change over time when returned to patients. These results will help improve engineered immunotherapy for melanoma and the assays will help understand a spectrum of other cellular immunotherapies in the future.